Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature

INTRODUCTION: Tumor necrosis factor (TNF-alpha) inhibitors, such as adalimumab, have shown success in treating autoimmune inflammatory diseases but are associated with substantial financial burdens to the healthcare system. Biosimilars, which are highly similar to biologic agents, offer the potentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Dongkuk, Yun, Jihoon, Hwang, Su-Jeong, Park, Su Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824449/
https://www.ncbi.nlm.nih.gov/pubmed/30554330
http://dx.doi.org/10.1007/s12325-018-0851-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824449/
https://www.ncbi.nlm.nih.gov/pubmed/30554330
http://dx.doi.org/10.1007/s12325-018-0851-5

Ejemplares similares